Brief: Nordic Nanovector Q1 Comprehensive Loss At NOK 105.1 Mln

Thor Medical ASA

13/05/2022 06:09

May 13 (Reuters) - Nordic Nanovector ASA  NANOVN.OL :
    * COMPREHENSIVE LOSS FOR Q1 2022 AMOUNTED TO NOK 105.1
MILLION
(LOSS OF NOK 102.1 MILLION)
    * REVENUES FOR Q1 2022 AMOUNTED TO NOK 0.0 MILLION (NOK 0.0
MILLION)
    * COMPANY'S CURRENT CASH POSITION WILL SUPPORT ITS
OPERATIONS INTO
H1'2023 AND WILL ENABLE FURTHER PREPARATORY WORK ON POTENTIAL
BETALUTIN® BLA FILING AND PLANNING FOR COMMERCIALISATION TO BE
UNDERTAKEN.
    * CONTINUES TO PURSUE OPPORTUNITIES FOR DEVELOPMENT AND
EXPANSION
OF ITS PIPELINE BASED ON CD37-TARGETING IMMUNOTHERAPIES

Source text for Eikon:  ID:nObiF8KFja 
Further company coverage:  NANOVN.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))